Cannabis Report
Home > Boards > US Listed > Biotechs >

GT Biopharma Inc. (GTBP)

GTBP RSS Feed
Add GTBP Price Alert      Hide Sticky   Hide Intro
Moderator: 236T568, CashBowski, Duke_DD_em, cleantrader, BullsOnFire, BlissTaxi
Search This Board: 
Last Post: 7/15/2018 9:06:01 PM - Followers: 179 - Board type: Free - Posts Today: 9

OTCQB: GTBP







The Scourge of Cancer

Cancer is the second leading cause of death globally, and responsible for 8.8 million deaths annually.  The economic impact of cancer is increasing. The total annual economic cost of cancer in 2015 was estimated at approximately US$ 2.5 trillion.  Immuno Oncology sits on the leading edge of cancer treatment and research.  In terms of effectiveness it promises to drastically outpace all previous forms of conventional cancer therapy.  Some estimate the Immuno Oncology market at $US 40 Billon and growing.



What is Immuno Oncology?

Immuno Oncology is treatment that recruits and supercharges a person's own immune system components to fight cancer. This can take various forms: the immune system can be stimulated to work harder or smarter in attacking cancer cells, immune system components can be supplied such as man-made immune proteins that attack cancer cells in a targeted way, immune system cells can be "programmed" to only attack very specific cancer cells or even to deliver a "payload" of compounds poisonous to cancer directly and only to the malignant cells. 
 

   




Immuno Oncology Goes Beyond Drawbacks of Conventional Chemotherapy
Conventional chemotherapy poisons the patient's body with the aim of getting the cancer too. Its like spraying a powerful herbicide on your rose garden to get rid of the dandelions. Yes, the weeds will die but the roses will suffer too.

With Immuno Oncology, the cure is not worse than the disease. Many of the harsh and debilitating side effects of chemotherapy are avoided because the agents that kill the cancer are components of the human immune system itself, rather than poison, and the therapy can be precisely targeted to only attack the cancerous cells.  It is truly the next evolutionary leap in cancer treatment.   




GT Biopharma Portfolio



GTBP Therapy Pipeline Highlights

OXS-1550: Treating Lymphoma and Leukemia
When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550, and are killed due to the action of drug’s cytotoxic diphtheria toxin payload.  OXS-1550 has demonstrated success in a Phase 1 human clinical trial in patients with relapsed/refractory B-cell lymphoma or leukemia.

The initial phase 1 study enrolled 25 patients (who) received at least a single course of therapy. The treatment at the higher doses produced objective tumor responses with one patient in continuous partial remission and the second in complete remission. Data from ongoing phase 2 expected in 2H ‘18.

OXS-3550: Treating Leukemia
The OXS-3550 IND will focus on AML, the most common form of adult leukemia with 21,000 new cases expected in 2017 alone (American Cancer Society). These patients will require frontline therapy, usually chemotherapy including cytarabine and an anthracycline, a therapy that has not changed in over 40 years.

OXS-1615 AND OXS-C3550: Treating Solid Tumors
This TetraKE is designed to kill not only the heterogeneous population of cancer cells found in solid tumors but also kill the cancer stem cells that are typically responsible for recurrences.



Other Offerings: Central Nervous System Therapies

GTP-011: Motion Sickness Treatment

GTP-011 is a 72-hour patch for which a patent application has been filed by GTP for the prevention of motion sickness, a well-known syndrome that typically involves nausea and vomiting in otherwise healthy people and that occurs upon exposure to certain types of motion.

PainBrake: Treating Neuropathic Pain 
PainBrake® is a new patented formulation of carbamazepine (Tegretol®) that enables accurate dose fractionation for the treatment of neuropathic pain.  An NIH-supported study estimated that almost 16 million Americans suffer from chronic neuropathic pain. Current drugs provide a useful degree of pain relief in only about half the patients. 

GTP-004: Treating Myasthenia Gravis
GTP-004 is a fixed-dose combination tablet for the treatment of myasthenia gravis. Myasthenia gravis is a chronic autoimmune disease of the neuromuscular junction characterized by muscle weakness. The prevalence of the disease in the United States is estimated at 14 to 20 per 100,000 population, approximately 36,000 to 60,000 cases in the U.S. 

 


GT Biopharma Executive Team: A Who's Who Of The Biotech Sector

"Look at Where Deutsche Bank’s Shawn Cross, Pfizer’s Dr. Raymond Urbanski, Chase Pharmaceutical’s Dr. Kathleen Clarence-Smith, and Barker Davis Founder Geoffrey Davis are making their bets.  Some of the biotech sector’s most affluent and influential individuals are making a move... to GT Biopharma Inc. (GTBP). This up-and-coming biotech company has a therapy pipeline that has attracted some of the industry’s most experienced leaders."




 



Company Website

GTBP Investor's Overview

GTBP News



Cannabis Report
GTBP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GTBP News: Current Report Filing (8-k) 07/05/2018 06:03:10 AM
GTBP News: GT BIOPHARMA ANNOUNCES UPDATE TO OXS-3550 IND FILING, ITS MOST ADVANCED TRI-SPECIFIC KILLER ENGAGER 05/16/2018 09:01:10 AM
GTBP News: Quarterly Report (10-q) 05/15/2018 06:12:45 PM
GTBP News: Current Report Filing (8-k) 05/14/2018 04:04:20 PM
GTBP News: Current Report Filing (8-k) 04/27/2018 04:03:53 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#14508  Sticky Note BIG NEWS: Voluntary Lock-Up Agreements With Insiders billymack 06/05/18 09:11:20 AM
#12195  Sticky Note DUKE's MASSIVE DD POST ON $GTBP or HOW Duke_DD_em 05/04/18 08:56:30 PM
#11766  Sticky Note $GTBP Exec Team Stacked with Superstars. The Duke_DD_em 05/01/18 02:58:41 PM
#9588  Sticky Note The topic of this board is OXIS. The CashBowski 03/31/17 11:03:34 AM
#15759   $2 break and run with another slap like ProlificPeter 07/15/18 09:06:00 PM
#15758   Not very liquid for a company with this Imvitium 07/15/18 04:23:12 PM
#15757   And on what sort of volume will this simon wagstaff 07/15/18 04:19:24 PM
#15756   All I am predicting is a 2.00 break Imvitium 07/15/18 03:59:01 PM
#15755   Assuming further updates coming regarding exec. team this PowerHourStocksAlert 07/15/18 03:54:43 PM
#15754   Agree 1.70 break and run Monday IMO. DipOp 07/15/18 03:43:47 PM
#15753   Very plausible. 1.70 has been hit into hard ProlificPeter 07/15/18 03:35:00 PM
#15752   Those 1.50 shares accumulated are looking pretty good PreMarketPicks 07/15/18 03:26:24 PM
#15751   Looking for a $2.00 break Monday. Thinking we Imvitium 07/15/18 03:04:07 PM
#15750   Thanks, I simply copy pasted what I linked PBGoodwill 07/14/18 11:08:02 PM
#15749   Hope everyone is watching next weeks action :) Imvitium 07/14/18 08:02:50 PM
#15748   Chart is ready for a $2.00 break here. KekStock 07/14/18 05:16:59 PM
#15747   Setting up here very nicely. Breaking 1.70 and PowerHourStocksAlert 07/14/18 05:02:42 PM
#15746   New CEO, and his extensive background are what Imvitium 07/14/18 03:33:10 PM
#15745   PB, Excellent Post on new CEO of GTBP. Stock62 07/14/18 12:54:27 PM
#15744   yep, green is always nice and considering its BubbleGum 07/13/18 04:34:45 PM
#15743   GTBP is becoming solid, more things to come BubbleGum 07/13/18 04:33:56 PM
#15742   nice closure of the week RevivalFire2018 07/13/18 04:33:06 PM
#15741   solid green up 3.03% RevivalFire2018 07/13/18 04:32:46 PM
#15740   Can we see more in this PH? ChicoRico 07/13/18 03:46:23 PM
#15739   Lovely bounce ChicoRico 07/13/18 03:46:06 PM
#15738   Sweet green 3% ChicoRico 07/13/18 03:45:50 PM
#15737   Agree. Need a couple more $4k slaps. Imvitium 07/13/18 03:42:38 PM
#15736   Is this neutral? Cocorito 07/13/18 03:42:01 PM
#15735   Still need some volume here Cocorito 07/13/18 03:40:08 PM
#15734   We've had plenty of em' Someone snagged 1870 ProlificPeter 07/13/18 03:37:27 PM
#15733   Where da' slaps at? KekStock 07/13/18 03:32:37 PM
#15730   GTBP CEO Shawn Cross ABRUPTLY resigns as CEO 236T568 07/13/18 03:10:40 PM
#15729   Scam company GTBP increases $1.8 million PAID STOCK 236T568 07/13/18 03:09:41 PM
#15728   Great base building. Huge bid in at 1.70 Imvitium 07/13/18 02:41:26 PM
#15727   Yeah, not sure why anyone would post that... ProlificPeter 07/13/18 02:35:47 PM
#15726   It's July 2018... Are you saying the campaign PreMarketPicks 07/13/18 02:29:33 PM
#15725   GTBP CEO Shawn Cross ABRUPTLY resigns as CEO 236T568 07/13/18 02:19:33 PM
#15724   Scam company GTBP increases $1.8 million PAID STOCK 236T568 07/13/18 02:18:56 PM
#15723   Mega bid in. Moving again from here. Imvitium 07/13/18 02:04:10 PM
#15722   Looks like it is back in play to me. KekStock 07/13/18 01:56:15 PM
#15721   saw you in here last month. I billymack 07/13/18 01:39:46 PM
#15720   Happening sooner! Agree 2.00 break coming here this Imvitium 07/13/18 01:38:09 PM
#15719   Very nice , I've heard alot of positive simmons420 07/13/18 01:37:55 PM
#15718   Nice Green run +6% for the day to Stock62 07/13/18 01:37:52 PM
#15717   Slaps slaps slaps. Early today. Excited for this afternoon! PreMarketPicks 07/13/18 01:28:38 PM
#15716   1.74s up! 2.00 clear today! PowerHourStocksAlert 07/13/18 01:23:00 PM
#15715   Looks like we're getting started early today?!? ProlificPeter 07/13/18 01:17:57 PM
#15714   Dip confirmed July 9/July 10 on GTBP billymack 07/13/18 01:04:54 PM
#15713   GTBP lock and Load we are going Green cleantrader 07/13/18 01:03:44 PM
#15712   Just added this back to my watch list LivH 07/13/18 12:49:11 PM
#15711   GM. You much of been watching Wednesday & Imvitium 07/13/18 12:48:49 PM
#15710   Chart ain't looking too bad here guys and billymack 07/13/18 12:47:02 PM
#15709   Good morning all. PreMarketPicks 07/13/18 12:40:51 PM
#15708   Smart. Good recommendation. I like the way you Imvitium 07/13/18 12:34:38 PM
PostSubject